Abstract: The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

Abstract: Systems, methods, and related technologies for segmentation management are described. In certain aspects, an entity communicatively coupled to a network is selected and one or more characteristics of the entity may be determined. A segmentation policy may be selected based on the one or more characteristics of the entity and one or more tags to be assigned to the entity based on the segmentation policy may be determined. A zone for the entity based on the one or more tags may be determined and one or more enforcement points associated with the zone for the entity may be determined. One or more enforcement actions may then be assigned to the one or more enforcement points based on the zone associated with the entity.

Abstract: The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

Abstract: A computerized method of facilitating participation in a feature operation executed in a game is provided. The computerized method comprises providing an aggregation platform operatively communicating with at least one remote game server (RGS). The RGS hosts at least one game to be provided to a plurality of players through players' devices. The method further comprises determining, in real time, eligibility of the plurality of players to participate in an operation of a feature shared between the players for a pre-configured event duration, wherein the shared feature operation is executed separately from the game. In response to determining that players are eligible players, facilitating their participation in the execution of the shared feature operation by iteratively selecting one eligible player as possessing a shared feature for a possession iteration having a respective possession duration, and granting an award feature to an eligible player that possesses the shared feature.

Abstract: Various aspects of this disclosure relate to topical anti-inflammatory, analgesic compositions comprising a fatty acid and tryptophan as well as methods of using such compositions. In some specific embodiments, the fatty acid is decanoic acid. Such compositions are generally useful to treat inflammation, and they are specifically useful to treat osteoarthritis.

Abstract: A computerized method of facilitating participation in a feature operation executed in a game is provided. The computerized method includes providing an aggregation platform operatively communicating with at least one remote game server (RGS). The RGS hosts at least one game to be provided to a plurality of players through players' devices. The method further includes determining, in real time, eligibility of the plurality of players to participate in an operation of a feature shared between the players for a pre-configured event duration, wherein the shared feature operation is executed separately from the game. In response to determining that players are eligible players, facilitating their participation in the execution of the shared feature operation by iteratively selecting one eligible player as possessing a shared feature for a possession iteration having a respective possession duration, and granting an award feature to an eligible player that possesses the shared feature.

Abstract: The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

Abstract: A converged device including a first subsystem and a second subsystem, configured to operate in multiple operation modes with varying levels of security. One example provides a method for operating the device. The method includes determining, during a startup sequence of the first subsystem and with a first processor of the first subsystem, a last operation mode for the first subsystem. The method includes determining, responsive to detecting that a SIM is installed in the converged device, a network type for the SIM. The method includes controlling, with the first processor, a first communication interface based on the network type and the last operation mode. The method includes determining, during a startup sequence of the second subsystem and with a second processor of the second subsystem, the last operation mode for the first subsystem and controlling, with the second processor, a second communication interface based on the last operation mode.

Abstract: A converged device including a first subsystem and a second subsystem, configured to operate in multiple operation modes with varying levels of security. One example provides a method for operating the device. The method includes determining, during a startup sequence of the first subsystem and with a first processor of the first subsystem, a last operation mode for the first subsystem. The method includes determining, responsive to detecting that a SIM is installed in the converged device, a network type for the SIM. The method includes controlling, with the first processor, a first communication interface based on the network type and the last operation mode. The method includes determining, during a startup sequence of the second subsystem and with a second processor of the second subsystem, the last operation mode for the first subsystem and controlling, with the second processor, a second communication interface based on the last operation mode.

Abstract: Systems, methods, and related technologies for segmentation management are described. In certain aspects, an entity communicatively coupled to a network is selected and one or more characteristics of the entity may be determined. A segmentation policy may be selected based on the one or more characteristics of the entity and one or more tags to be assigned to the entity based on the segmentation policy may be determined. A zone for the entity based on the one or more tags may be determined and one or more enforcement points associated with the zone for the entity may be determined. One or more enforcement actions may then be assigned to the one or more enforcement points based on the zone associated with the entity.

Abstract: Systems, methods, and related technologies for segmentation management are described. In certain aspects, an entity communicatively coupled to a network is selected and one or more characteristics of the entity may be determined. A segmentation policy may be selected based on the one or more characteristics of the entity and one or more tags to be assigned to the entity based on the segmentation policy may be determined. A zone for the entity based on the one or more tags may be determined and one or more enforcement points associated with the zone for the entity may be determined. One or more enforcement actions may then be assigned to the one or more enforcement points based on the zone associated with the entity.

Abstract: Devices and systems for providing cross-agency communications at an incident are described. An incident manager determines attributes of devices to be used at the incident, negotiating the devices and device attributes with each first responder agency from which devices are to be dispatched to the incident. The manager controls lifecycles of network slices to provide communication services for the incident. The lifecycle is controlled based on communication from each UE indicating arrival to and departure from the incident, as well as the attributes of the UE.

Abstract: The invention provides a method, composition and kit for treating T-cell mediated diseases, degenerative joint diseases or diseases mediated by platelet activating factor (PAF) comprising administering to an animal in need thereof, an effective amount a pharmaceutical composition containing N-acetyl-kynurenine (NAK) or pharmaceutically acceptable salts thereof as the active ingredient.

Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.

Abstract: The present invention provides a method of modulating various aspects of the immune system. In particular, the present invention teaches the use of diketopiperazines (DKPs) to modulate various aspects of the immune system such as, for example, inflammation, T-cells and various cytokines.

Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.

Abstract: A computerized method of facilitating participation in a feature operation executed in a game is provided. The computerized method comprises providing an aggregation platform operatively communicating with at least one remote game server (RGS). The RGS hosts at least one game to be provided to a plurality of players through players' devices. The method further comprises determining, in real time, eligibility of the plurality of players to participate in an operation of a feature shared between the players for a pre-configured event duration, wherein the shared feature operation is executed separately from the game. In response to determining that players are eligible players, facilitating their participation in the execution of the shared feature operation by iteratively selecting one eligible player as possessing a shared feature for a possession iteration having a respective possession duration, and granting an award feature to an eligible player that possesses the shared feature.

Abstract: The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP.

Abstract: Devices and systems for providing cross-agency communications at an incident are described. An incident manager determines attributes of devices to be used at the incident, negotiating the devices and device attributes with each first responder agency from which devices are to be dispatched to the incident. The manager controls lifecycles of network slices to provide communication services for the incident. The lifecycle is controlled based on communication from each UE indicating arrival to and departure from the incident, as well as the attributes of the UE.